{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073689","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.071391+00:00","generated_at":"2026-05-15T23:31:20.246290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fate Therapeutics Q4: cash $205M, OpEx down 30%, FT819 outpatient treatment milestone","bullets":["Cash and investments $205.1M as of Dec 31, 2025; operating runway through year-end 2027.","Q4 revenue $1.4M from Ono collaboration; total operating expenses $36.1M (R&D $25.4M, G&A $10.7M).","FT819 off-the-shelf CAR T: 15 SLE, 4 SSc, 1 IIM patients treated; outpatient same-day discharge achieved.","FT836 (Sword & Shield) in CRC: first patient shows >50% CEA reduction and tumor shrinkage at DL1 without conditioning chemo.","Operating expenses reduced 30% in 2025 vs 2024; common shares 115.4M, pre-funded warrants 3.9M, preferred 2.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073689","json":"https://secwatch.observer/filing/0001193125-26-073689.json","markdown":"https://secwatch.observer/filing/0001193125-26-073689.md","text":"https://secwatch.observer/filing/0001193125-26-073689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526073689/0001193125-26-073689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526073689/fate-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:31:20.246290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}